This inventor holds 1 USPTO granted patent. Top assignee: Cellex Corporation. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Jun-ichi Masuyama: Innovator in Immunotherapy for Pancreatic Cancer
Introduction
Jun-ichi Masuyama is a prominent inventor based in Oyama, Japan. She has made significant contributions to the field of immunotherapy, particularly in the treatment of pancreatic cancer. Her innovative approach aims to extend the survival time of patients suffering from this challenging disease.
Latest Patents
Masuyama holds a patent for an immunotherapeutic agent designed specifically for pancreatic cancer. The invention involves culturing peripheral blood lymphocytes from patients and stimulating them with anti-CD3 and anti-CD52 antibodies. This process results in an immunotherapeutic agent that is administered through at least four infusions, each containing a substantial number of activated lymphocytes. The treatment is tailored for patients in specific immunocompromised states, showcasing her dedication to improving patient outcomes.
Career Highlights
Masuyama is associated with Cellex Corporation, where she continues to advance her research and development efforts. Her work has garnered attention for its potential to revolutionize cancer treatment, particularly for those with limited options. The focus on immunotherapy reflects a growing trend in medical research aimed at harnessing the body's immune system to fight cancer.
Conclusion
Jun-ichi Masuyama's innovative contributions to immunotherapy represent a significant advancement in the fight against pancreatic cancer. Her dedication to improving patient survival through groundbreaking research is commendable.